Resveratrol Cognition Meta-analysis: What the Evidence Says

Quick Answer

Resveratrol Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Kaur et al., 2022 Figure 1 Figure 1 Ko et al., 2017 Tanwar et al., 2021 Qasem, 2020 Zhang et al., 2021 Resveratrol, a polyphenolic phytoalexin in the stilbene family, is commonly found in grape skins, red wine, peanuts, and certain berries. [Wu Weidong (2025); evidence level 1]
• Due to elevated follicle-stimulating hormone levels and significantly reduced estrogen levels, postmenopausal women face a variety of health challenges, including an increased risk of osteoporosis, mental health symptoms, cognitive decline, cardiovascular disease, and metabolic syndrome, all of which pose a substantial medical burden to both individuals and society (;). [Wu Weidong (2025); evidence level 1]
• In parallel, epidemiological evidence has consistently linked specific dietary patterns, such as the Mediterranean and MIND diets, to a reduced risk of cognitive decline and AD. [Kumari Ankita (2026); evidence level 2]
• These changes progress to reduced brain volume and are responsible for the memory loss associated with AD. [Kumari Ankita (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For resveratrol cognition meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Wu Weidong (2025). Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis. DOI: 10.3389/fphar.2025.1588284. PMCID: PMC12325339. PMID: 40771919. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12325339/
• Kumari Ankita (2026). Dietary Bioactives in Alzheimer’s Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. DOI: 10.3390/nu18060907. PMCID: PMC13029159. PMID: 41901082. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029159/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.